Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

Determining the effects of past gold mining using a sediment palaeotoxicity model.

Cheney CL, Eccles KM, Kimpe LE, Thienpont JR, Korosi JB, Blais JM.

Sci Total Environ. 2020 Feb 14;718:137308. doi: 10.1016/j.scitotenv.2020.137308. [Epub ahead of print]

PMID:
32088480
2.

Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells.

Do P, Beckwith KA, Cheney C, Tran M, Beaver L, Griffin BG, Mo X, Liu Y, Lapalombella R, Hertlein E, Muthusamy N, Byrd JC.

J Immunol. 2019 May 1;202(9):2806-2816. doi: 10.4049/jimmunol.1801359. Epub 2019 Mar 25.

PMID:
30910862
3.

Scenarios for the management of invasive Acacia species in a protected area: Implications of clearing efficacy.

Cheney C, Esler KJ, Foxcroft LC, van Wilgen NJ.

J Environ Manage. 2019 May 15;238:274-282. doi: 10.1016/j.jenvman.2019.02.112. Epub 2019 Mar 7.

PMID:
30852404
4.

Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.

McWilliams EM, Lucas CR, Chen T, Harrington BK, Wasmuth R, Campbell A, Rogers KA, Cheney CM, Mo X, Andritsos LA, Awan FT, Woyach J, Carson WE 3rd, Butchar J, Tridandapani S, Hertlein E, Castro CE, Muthusamy N, Byrd JC.

Blood Adv. 2019 Feb 12;3(3):447-460. doi: 10.1182/bloodadvances.2018025684.

5.

Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.

Reiff SD, Muhowski EM, Guinn D, Lehman A, Fabian CA, Cheney C, Mantel R, Smith L, Johnson AJ, Young WB, Johnson AR, Liu L, Byrd JC, Woyach JA.

Blood. 2018 Sep 6;132(10):1039-1049. doi: 10.1182/blood-2017-10-809020. Epub 2018 Jul 17.

6.

[Risk Prediction Using Routine Data: Development and Validation of Multivariable Models Predicting 30- and 90-day Mortality after Surgical Treatment of Colorectal Cancer].

Crispin A, Strahwald B, Cheney C, Mansmann U.

Gesundheitswesen. 2018 Nov;80(11):963-973. doi: 10.1055/a-0592-6826. Epub 2018 Jun 4. German.

PMID:
29864770
7.

Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia.

Gopalakrishnan B, Cheney C, Mani R, Mo X, Bucci D, Walker A, Klisovic R, Bhatnagar B, Walsh K, Rueter B, Waizenegger IC, Heider KH, Blum W, Vasu S, Muthusamy N.

Oncotarget. 2018 Jan 3;9(11):9706-9713. doi: 10.18632/oncotarget.23880. eCollection 2018 Feb 9.

8.

The Association between Serum 25-Hydroxyvitamin D and Cancer Risk: Results from the Prospective KORA F4 Study.

Cheney CP, Thorand B, Huth C, Berger K, Peters A, Seifert-Klauss V, Kiechle M, Strauch K, Quante AS.

Oncol Res Treat. 2018;41(3):117-121. doi: 10.1159/000485512. Epub 2018 Feb 27.

9.

Response to Protocol Review Scenario: Make the leap of faith, but finish looking first.

Cheney CA.

Lab Anim (NY). 2018 Jan 31;47(2):29-30. doi: 10.1038/laban.1401. No abstract available.

PMID:
29384516
10.

Immobilization of Methylosinus trichosporium OB3b for methanol production.

Taylor A, Molzahn P, Bushnell T, Cheney C, LaJeunesse M, Azizian M, Semprini L.

J Ind Microbiol Biotechnol. 2018 Mar;45(3):201-211. doi: 10.1007/s10295-018-2010-z. Epub 2018 Jan 19.

PMID:
29350313
11.

Ibrutinib treatment improves T cell number and function in CLL patients.

Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, Andritsos LA, Awan F, Fraietta JA, June CH, Maus MV, Woyach JA, Caligiuri MA, Johnson AJ, Muthusamy N, Byrd JC.

J Clin Invest. 2017 Aug 1;127(8):3052-3064. doi: 10.1172/JCI89756. Epub 2017 Jul 17.

12.

A ranking system for prescribed burn prioritization in Table Mountain National Park, South Africa.

Cowell CR, Cheney C.

J Environ Manage. 2017 Apr 1;190:283-289. doi: 10.1016/j.jenvman.2016.12.070. Epub 2017 Jan 5.

PMID:
28064035
13.

Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia.

McWilliams EM, Mele JM, Cheney C, Timmerman EA, Fiazuddin F, Strattan EJ, Mo X, Byrd JC, Muthusamy N, Awan FT.

Oncoimmunology. 2016 Sep 9;5(10):e1226720. eCollection 2016.

14.

Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.

Vasu S, He S, Cheney C, Gopalakrishnan B, Mani R, Lozanski G, Mo X, Groh V, Whitman SP, Konopitzky R, Kössl C, Bucci D, Lucas DM, Yu J, Caligiuri MA, Blum W, Adam PJ, Borges E, Rueter B, Heider KH, Marcucci G, Muthusamy N.

Blood. 2016 Jun 9;127(23):2879-89. doi: 10.1182/blood-2015-11-680546. Epub 2016 Mar 24.

15.

Granzyme B expression is enhanced in human monocytes by TLR8 agonists and contributes to antibody-dependent cellular cytotoxicity.

Elavazhagan S, Fatehchand K, Santhanam V, Fang H, Ren L, Gautam S, Reader B, Mo X, Cheney C, Briercheck E, Vasilakos JP, Dietsch GN, Hershberg RM, Caligiuri M, Byrd JC, Butchar JP, Tridandapani S.

J Immunol. 2015 Mar 15;194(6):2786-95. doi: 10.4049/jimmunol.1402316. Epub 2015 Feb 9.

16.

Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.

Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R, Johnson AJ, Byrd JC.

Blood. 2014 Mar 20;123(12):1957-60. doi: 10.1182/blood-2014-01-547869. No abstract available.

17.

Histone H1 phosphorylation in breast cancer.

Harshman SW, Hoover ME, Huang C, Branson OE, Chaney SB, Cheney CM, Rosol TJ, Shapiro CL, Wysocki VH, Huebner K, Freitas MA.

J Proteome Res. 2014 May 2;13(5):2453-67. doi: 10.1021/pr401248f. Epub 2014 Apr 7.

18.

Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.

Cheney CM, Stephens DM, Mo X, Rafiq S, Butchar J, Flynn JM, Jones JA, Maddocks K, O'Reilly A, Ramachandran A, Tridandapani S, Muthusamy N, Byrd JC.

MAbs. 2014 May-Jun;6(3):749-55. doi: 10.4161/mabs.28282. Epub 2014 Mar 4.

19.

The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model.

Beckwith KA, Frissora FW, Stefanovski MR, Towns WH, Cheney C, Mo X, Deckert J, Croce CM, Flynn JM, Andritsos LA, Jones JA, Maddocks KJ, Lozanski G, Byrd JC, Muthusamy N.

Leukemia. 2014 Jul;28(7):1501-10. doi: 10.1038/leu.2014.32. Epub 2014 Jan 21.

20.

Fcγ receptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies.

Justiniano SE, Elavazhagan S, Fatehchand K, Shah P, Mehta P, Roda JM, Mo X, Cheney C, Hertlein E, Eubank TD, Marsh C, Muthusamy N, Butchar JP, Byrd JC, Tridandapani S.

J Biol Chem. 2013 Sep 13;288(37):26800-9. doi: 10.1074/jbc.M113.485185. Epub 2013 Jul 31.

21.

Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.

Rafiq S, Siadak A, Butchar JP, Cheney C, Lozanski G, Jacob NK, Lapalombella R, McGourty J, Moledor M, Lowe R, Setter B, Jones J, Flynn JM, Andritsos L, Devine S, Mo X, Jarjoura D, Tridandapani S, Algate P, Byrd JC, Muthusamy N.

MAbs. 2013 Sep-Oct;5(5):723-35. doi: 10.4161/mabs.25282. Epub 2013 Jun 7.

22.

Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis.

Barnard RJ, McHale CM, Newhard W, Cheney CA, Graham DJ, Himmelberger AL, Strizki J, Hwang PM, Rivera AA, Reeves JD, Nickle D, Dinubile MJ, Hazuda DJ, Mobashery N.

Virology. 2013 Sep 1;443(2):278-84. doi: 10.1016/j.virol.2013.05.013. Epub 2013 Jun 10.

23.

Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.

Rafiq S, Butchar JP, Cheney C, Mo X, Trotta R, Caligiuri M, Jarjoura D, Tridandapani S, Muthusamy N, Byrd JC.

J Immunol. 2013 Mar 15;190(6):2702-11. doi: 10.4049/jimmunol.1202588. Epub 2013 Feb 15.

24.

Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.

Yu B, Mao Y, Bai LY, Herman SE, Wang X, Ramanunni A, Jin Y, Mo X, Cheney C, Chan KK, Jarjoura D, Marcucci G, Lee RJ, Byrd JC, Lee LJ, Muthusamy N.

Blood. 2013 Jan 3;121(1):136-47. doi: 10.1182/blood-2012-01-407742. Epub 2012 Nov 19.

25.

Amending a protocol to import and breed knockout mice. New strains, strain-free.

Cheney C, Kline L, Wilber C.

Lab Anim (NY). 2012 Mar 20;41(4):98-9. doi: 10.1038/laban0412-98a. No abstract available.

PMID:
22430473
26.

XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells.

Rafiq S, Cheney C, Mo X, Jarjoura D, Muthusamy N, Byrd JC.

Leukemia. 2012 Jul;26(7):1720-2. doi: 10.1038/leu.2012.40. Epub 2012 Feb 15. No abstract available.

27.

Distinct expression profiles of Notch-1 protein in human solid tumors: Implications for development of targeted therapeutic monoclonal antibodies.

Li Y, Burns JA, Cheney CA, Zhang N, Vitelli S, Wang F, Bett A, Chastain M, Audoly LP, Zhang ZQ.

Biologics. 2010 Jun 24;4:163-71.

28.

National e-Health Summit 2009: A Comprehensive Overview of Electronic Health Management. Sydney 27-28 July 2009.

Collen J, Cheney C, Georgy S, White L.

Health Inf Manag. 2010 Jun;39(2):53-55. doi: 10.1177/183335831003900211. No abstract available.

PMID:
28683641
29.

In vivo wireless ethanol vapor detection in the Wistar rat.

Cheney CP, Srijanto B, Hedden DL, Gehl A, Ferrell TL, Schultz J, Engleman EA, McBride WJ, O'Connor S.

Sens Actuators B Chem. 2009 Apr 24;138(1):264-269.

30.

Differential effects of IL-2 and IL-21 on expansion of the CD4+ CD25+ Foxp3+ T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia.

Gowda A, Ramanunni A, Cheney C, Rozewski D, Kindsvogel W, Lehman A, Jarjoura D, Caligiuri M, Byrd JC, Muthusamy N.

MAbs. 2010 Jan-Feb;2(1):35-41. Epub 2010 Jan 8.

31.

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.

Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM Jr, Roda JM, Cheney C, Mo X, Lehman A, Jones J, Flynn J, Jarjoura D, Desjarlais JR, Tridandapani S, Caligiuri MA, Muthusamy N, Byrd JC.

Blood. 2010 Feb 11;115(6):1204-13. doi: 10.1182/blood-2009-06-229039. Epub 2009 Dec 2.

32.

Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia.

Lin TS, Naumovski L, Lecane PS, Lucas MS, Moran ME, Cheney C, Lucas DM, Phan SC, Miller RA, Byrd JC.

Leuk Lymphoma. 2009 Dec;50(12):1977-82. doi: 10.3109/10428190903288464.

PMID:
19860624
33.

A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.

Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC.

Leuk Lymphoma. 2009 Dec;50(12):1958-63. doi: 10.3109/10428190903186486.

PMID:
19860603
34.

Carmel Cheney: Health Information Management Consultant.

Cheney C.

Health Inf Manag. 2009 Oct;38(3):69-71. doi: 10.1177/183335830903800312. No abstract available.

PMID:
28762853
35.

A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses.

Harbecke R, Oxman MN, Arnold BA, Ip C, Johnson GR, Levin MJ, Gelb LD, Schmader KE, Straus SE, Wang H, Wright PF, Pachucki CT, Gershon AA, Arbeit RD, Davis LE, Simberkoff MS, Weinberg A, Williams HM, Cheney C, Petrukhin L, Abraham KG, Shaw A, Manoff S, Antonello JM, Green T, Wang Y, Tan C, Keller PM; Shingles Prevention Study Group.

J Med Virol. 2009 Jul;81(7):1310-22. doi: 10.1002/jmv.21506.

36.

A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Woyach JA, Lin TS, Lucas MS, Heerema N, Moran ME, Cheney C, Lucas DM, Wei L, Caligiuri MA, Byrd JC.

Leukemia. 2009 May;23(5):912-8. doi: 10.1038/leu.2008.385. Epub 2009 Feb 19.

37.

The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.

Lapalombella R, Gowda A, Joshi T, Mehter N, Cheney C, Lehman A, Chen CS, Johnson AJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC.

Br J Haematol. 2009 Mar;144(6):848-55. doi: 10.1111/j.1365-2141.2008.07548.x. Epub 2009 Jan 12.

38.

The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma.

Joshi T, Ganesan LP, Cheney C, Ostrowski MC, Muthusamy N, Byrd JC, Tridandapani S.

PLoS One. 2009;4(1):e4208. doi: 10.1371/journal.pone.0004208. Epub 2009 Jan 16.

39.

Choice of fixative is crucial to successful immunohistochemical detection of phosphoproteins in paraffin-embedded tumor tissues.

Burns JA, Li Y, Cheney CA, Ou Y, Franlin-Pfeifer LL, Kuklin N, Zhang ZQ.

J Histochem Cytochem. 2009 Mar;57(3):257-64. doi: 10.1369/jhc.2008.952911. Epub 2008 Nov 11.

40.

Drug menus in protocol applications. A la carte is OK.

Cheney CA.

Lab Anim (NY). 2008 Sep;37(9):398-9. doi: 10.1038/laban0908-398b. No abstract available.

PMID:
18719688
41.

A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.

Lapalombella R, Zhao X, Triantafillou G, Yu B, Jin Y, Lozanski G, Cheney C, Heerema N, Jarjoura D, Lehman A, Lee LJ, Marcucci G, Lee RJ, Caligiuri MA, Muthusamy N, Byrd JC.

Clin Cancer Res. 2008 Jan 15;14(2):569-78. doi: 10.1158/1078-0432.CCR-07-1006.

42.

IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro.

Gowda A, Roda J, Hussain SR, Ramanunni A, Joshi T, Schmidt S, Zhang X, Lehman A, Jarjoura D, Carson WE, Kindsvogel W, Cheney C, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC.

Blood. 2008 May 1;111(9):4723-30. doi: 10.1182/blood-2007-07-099531. Epub 2008 Jan 8.

43.

Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines.

Pathan NI, Chu P, Hariharan K, Cheney C, Molina A, Byrd J.

Blood. 2008 Feb 1;111(3):1594-602. Epub 2007 Nov 21.

PMID:
18032710
44.

Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.

Johnson AJ, Wagner AJ, Cheney CM, Smith LL, Lucas DM, Guster SK, Grever MR, Lin TS, Byrd JC.

Br J Haematol. 2007 Dec;139(5):837-44. Epub 2007 Oct 19.

PMID:
17949452
45.

Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.

Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS, Baum PR, Lin TS, Jarjoura D, Lehman A, Kussewitt D, Lee RJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC.

Blood. 2007 Oct 1;110(7):2569-77. Epub 2007 Apr 17.

46.

Effect of previous locoweed (Astragalus and Oxytropis species) intoxication on conditioned taste aversions in horses and sheep.

Pfister JA, Stegelmeier BL, Cheney CD, Gardner DR.

J Anim Sci. 2007 Jul;85(7):1836-41. Epub 2007 Apr 12.

PMID:
17431041
47.

Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity.

Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA, Lucas DM, Byrd JC.

Clin Cancer Res. 2007 Apr 1;13(7):2144-50.

48.

Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism.

Mone AP, Cheney C, Banks AL, Tridandapani S, Mehter N, Guster S, Lin T, Eisenbeis CF, Young DC, Byrd JC.

Leukemia. 2006 Feb;20(2):272-9.

PMID:
16341049
50.

Role of Rab GTPases in Recruitment of Myosin- V to Vesicles of Squid Giant Axon.

You SM, Cheney C, Swiatecka-Urban A, Langford GM.

Biol Bull. 2004 Oct;207(2):163. No abstract available.

PMID:
27690615

Supplemental Content

Loading ...
Support Center